Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism

Liang, Guang; Song, Lintao; Chen, Zilu; Qian, Yuanyuan; Xie, Jingyuan; Zhao, Lingyue; Lin, Qian; Zhu, Guo‐Qing; Tan, Yi; Li, Xiaokun; Mohammadi, Moosa; Huang, Zhifeng

doi:10.1016/j.kint.2017.05.013

Cited by 120 publications

(114 citation statements)

References 45 publications

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…Specific treatment of patients with diabetic nephropathy can be divided into 4 major arenas: cardiovascular risk reduction, glycemic control, blood pressure control, and inhibition of the renin‐angiotensin system (RAS) . Our previous studies have demonstrated that FGF1 administration protected against renal injury by reducing inflammation . Based on previous study, our current study had further confirmed that FGF1 administration ameliorated diabetes‐induced glomerular damage and interstitial fibrosis.…”

Section: Discussionsupporting

confidence: 64%

“…Fibroblast growth factor 1 (FGF1) is an autocrine/paracrine regulator and known to act on cells from a variety of tissue origins including the liver, vasculature, and skin, exerting classic mitogenic activity and neuroprotective role . Our previous study had demonstrated that FGF1 treatment ameliorated diabetes‐induced nephropathy by inhibiting inflammation via JNK/NF‐kB signalling pathway . But there are no studies to focus on the effect of FGF1 on cellular stress during FGF1 treatment for DN.…”

Section: Introductionmentioning

confidence: 99%

“…12 Our previous study had demonstrated that FGF1 treatment ameliorated diabetes-induced nephropathy by inhibiting inflammation via JNK/NF-kB signalling pathway. 13 But there are no studies to focus on the effect of FGF1 on cellular stress during FGF1 treatment for DN. It is well known that hyperglycemia resulting in glucotoxicity is the main factor for diabetes-induced complications.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Reduction of cellular stress is essential for Fibroblast growth factor 1 treatment for diabetic nephropathy

Jiang

et al. 2018

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is one of general and common complication of diabetes, which severely affects the physical and mental health of diabetic patients. Fibroblast growth factor 1 (FGF1), an effective control agent of blood glucose, plays an effective treatment role on diabetes‐induced renal injury. But the specific molecule mechanism underlying it is still unclear. Since induction of cellular stress is the main and common mechanism of diabetes‐induced complication, we hypothesized that reduction of cellular stress is also the molecular mechanism of FGF1 treatment for DN. Here, we have further confirmed that FGF1 significantly ameliorated the diabetes‐induced renal interstitial fibrosis and glomerular damage. The expression levels of collagen and α‐smooth muscle actin (α‐SMA) also dramatically induced in kidney from db/db mice, but these effects were blocked by FGF1 administration. Our mechanistic investigation had further revealed that diabetes significantly induced oxidative stress, nitrosative stress, and endoplasmic reticulum (ER) stress with upregulation of malondialdehyde (MDA), nitrotyrosine level, ER stress makers and downregulation of antioxidant capacity (AOC). FGF1 treatment significantly attenuated the effect of diabetes on cellular stress. We conclude that FGF1‐associated glucose decreases and subsequent reduction of cellular stress is the another potential molecule mechanism underlying FGF1 treatment for DN.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Reduction of cellular stress is essential for Fibroblast growth factor 1 treatment for diabetic nephropathy

Jiang

et al. 2018

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

show abstract

“…JNK and NF‐κB signalling pathways are involved in the expression of α‐SMA and collagen 7, 8. Protein levels of p‐JNK and NF‐κB were increased in LX‐2 cells activated by TGF‐β1, and this increase was inhibited by FGF21_ADSCs CM treatment but not by Empty_ADSCs CM or 200 pg/mL FGF21 (Figure 2C,D).…”

Section: Resultsmentioning

confidence: 95%

Effects of FGF21‐secreting adipose‐derived stem cells in thioacetamide‐induced hepatic fibrosis

Kang

Seo

Park

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have been investigated to treat liver diseases, but the efficiency of MSCs to treat chronic liver diseases is conflicting. FGF21 can reduce inflammation and fibrosis. We established FGF21‐secreting adipose derived stem cells (FGF21_ADSCs) to enhance the effects of ADSCs and transplanted them into thioacetamide (TAA)‐induced liver fibrosis mice via the tail vein. Transplantation of FGF21_ADSCs significantly improved liver fibrosis by decreasing serum hyaluronic acid and reducing the expression of fibrosis‐related factors such as α‐smooth muscle actin (α‐SMA), collagen and tissue inhibitor of metalloproteinase‐1 (TIMP‐1) compared with the Empty_ADSCs by inhibition of p‐JNK, NF‐κB and p‐Smad2/3 signalling. α‐lactoalbumin (LA) and lactotransferrin (LTF), secretory factors produced from FGF21_ADSCs inhibited TGF‐β1‐induced expression of α‐SMA and collagen in LX‐2 cells. These results suggest that transplantation of FGF21_ADSCs inhibited liver fibrosis more effectively than Empty_ADSCs, possibly via secretion of α‐LA and LTF.

show abstract

“…In the year 2018, several compounds like berberine, gallic acid, ligustrazine, nifuroxazide, pentoxifylline, rosuvastatin, and so forth to treat kidney damage in type 1 diabetes and compounds like dihydroquercetin, cinacalcet, cyanidin‐3‐O‐glucoside, zingerone, glucagon‐like peptide‐1 (GLP‐1) co‐agonist, dapagliflozin, pioglitazone, and fibroblast growth factor 1 to treat kidney damage in type 2 diabetes have been studied so far. Compound like carnosic acid was found to ameliorate kidney damage in both type 1 and type 2 diabetes (Ding et al, ; Elhawary, Ibrahim, & Attallah, ; Elsherbiny, Zaitone, Mohammad, & El‐Sherbiny, ; Garud & Kulkarni, ; Han et al, ; Liang et al, ; Lim et al, ; Patel et al, ; Qin et al, ; Rehman et al, ; Xie et al, ; Yang & Wu, ; Zhu, Han, Yuan, Xue, & Pang, ).…”

Section: Introductionmentioning

confidence: 99%

Cognitive dysfunction: A growing link between diabetes and Alzheimer's disease

Jash

Gondaliya

Kirave

et al. 2019

Drug Development Research

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a gradually rising metabolic disease which is currently affecting millions of people worldwide. Diabetes is associated with various complications like nephropathy, neuropathy, retinopathy, diabetic foot, cognitive impairment, and many more. Evidence suggests that cognitive dysfunction is a rising complication of diabetes which adversely affects the brain of patients suffering from diabetes. Age‐related memory impairment is a complication having its major effect on people suffering from diabetes and Alzheimer's. Patients suffering from diabetes are at two times higher risk of developing cognitive dysfunction as compared with normal individuals. Multiple factors which are involved in diabetes related complications are found to play a role in the development of neurodegeneration in Alzheimer's. The problem of insulin deficiency and insulin resistance is well reported in diabetes but there are many studies which suggest dysregulation of insulin levels as a reason behind the development of Alzheimer's. As the link between diabetes and Alzheimer disease (AD) is deepening, there is a need to understand the plausible tie‐ins between the two. Emerging role of major factors like insulin imbalance, advanced glycation end products and micro‐RNA's involved in diabetes and Alzheimer's have been discussed here. This review helps in understanding the plausible mechanism underlying the pathophysiology of amyloid beta (Aβ) plaque formation and tau hyperphosphorylation as well provides information about studies carried out in this area of research. The final thought is to enhance the scientific knowledge on this correlation and develop future therapeutics to treat the same.

show abstract

Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism

Cited by 120 publications

References 45 publications

Reduction of cellular stress is essential for Fibroblast growth factor 1 treatment for diabetic nephropathy

Reduction of cellular stress is essential for Fibroblast growth factor 1 treatment for diabetic nephropathy

Effects of FGF21‐secreting adipose‐derived stem cells in thioacetamide‐induced hepatic fibrosis

Cognitive dysfunction: A growing link between diabetes and Alzheimer's disease

Contact Info

Product

Resources

About